Novel psychoactive substances (NPS): clinical and pharmacological issues
Author:
Schifano Fabrizio
Abstract
Purpose
– The purpose of this paper is to provide health professionals with novel psychoactive substances (NPS) clients with up to date information relating to the background, clinical pharmacology and, when possible, clinical management for each of these categories.
Design/methodology/approach
– The world of NPS is complex and diverse, including a range of different molecules such as: psychedelic phenethylamines; synthetic cannabinoids, cathinone derivatives; novel stimulants; synthetic opiates/opioids; tryptamine derivatives; phencyclidine-like dissociatives; piperazines; GABA-A/GABA-B receptor agonists; a range of prescribing medications; psychactive plants/herbs; and a large series of performance and image-enhancing drugs. These molecules are sought by users for their psychactive effects.
Findings
– The NPS categorization and classification provided here is an attempt to identify and better understand some of these substances. Given the vast range of medical and psychopathological issues associated with the NPS described it is crucial for health professionals to be aware of the effects and toxicity of NPS. The EU-MADNESS project aims to both better understand the pharmacology of the available/forthcoming NPS and to disseminate the most current NPS-related information to practising and training health professionals.
Research limitations/implications
– Further studies are required to identify a range of evidence-based, NPS-focused, clinical management and treatment strategies.
Social implications
– The rapid pace of change in the NPS online market constitutes a major challenge to the provision of current and reliable scientific knowledge on these substances.
Originality/value
– The present review will provide an overview of the clinical and pharmacological issues related to a few hundred NPS.
Subject
Psychiatry and Mental health,Clinical Psychology,Medicine (miscellaneous)
Reference28 articles.
1. Bersani, F.S.
,
Corazza, O.
,
Albano, G.
,
Valeriani, G.
,
Santacroce, R.
,
Cinosi, E.
,
Simonato, P.
,
Martinotti, G.
,
Bersani, G.
,
Schifano, F.
and
Bolzan, F.
(2014), “25C-NBOMe: preliminary data on pharmacology, psychoactive effects and toxicity of a new potent and dangerous hallucinogenic drug”,
BioMed Research International
. 2. Brandt, S.D.
,
Baumann, M.H.
,
Partilla, J.S.
,
Kavanagh, P.V.
,
Power, J.D.
,
Talbot, B.
,
Twamley, B.
,
Mahony, O.
,
O'Brien, J.
,
Elliott, S.P.
,
Archer, R.P.
,
Patrick, J.
,
Singh, K.
,
Dempster, N.M.
and
Cosbey, S.H.
(2014), “Characterization of a novel and potentially lethal designer drug (±)-cis-para-methyl-4-methylaminorex (4,4’-DMAR, or ‘Serotoni’)”,
Drug Testing Analysis
, Vol. 6 No. 7, pp. 684-95. 3. Chiappini, S.
,
Claridge, H.
,
Corkery, J.
,
Gimeno Clemente, C.
,
Goodair, C.
,
Loi, B.
and
Schifano, F.
(in press), “Methoxetamine related fatalities in the UK”,
Human Psychopharmacology Clinical and Experimental
. 4. Corazza, O.
and
Schifano, F.
(2010), “Ketamine-induced ‘near-death experience’ states in a sample of 50 misusers”,
Substance Use and Misuse
, Vol. 45 No. 6, pp. 916-24. 5. Corazza, O.
,
Bersani, F.S.
,
Brunoro, R.
,
Valeriani, G.
,
Martinotti, G.
and
Schifano, F.
(2014), “Performance and image enhancing drugs: the abuse of cognitive enhancer Piracetam”,
Substance Use and Misuse
, Vol. 49 No. 14, pp. 1849-56.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|